Best of ASCO - 2014 Annual Meeting

 

Welcome

Adjuvant Therapy

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A novel approach to capture patient-reported toxicities of immunotherapy for non-small cell lung cancer using a foundation-sponsored patient registry.

Heather S.L. Jim

e20506

Association of base excision repair gene polymorphisms with response to chemotherapy of advanced non small-cell lung cancer in a Chinese population.

Jie Dong

e20504

Comparative efficacy and safety of Pemetrexed or paclitaxel plus thoracic radiation therapy (TRT) in elderly patients with nonsquamous locally advanced NSCLC.

Ge Bai

8509

EA5142 adjuvant nivolumab in resected lung cancers (ANVIL).

Jamie E. Chaft

TPS8581

Effects of comprehensive genomic testing in a large non-small cell cancer NSCLC cohort: Racial and survival impacts.

Fatemeh Ardeshir-Larijani

8526

Effects of TKI on patients with non-small cell lung cancer of different stages: A meta-analysis.

Di Lu

e20503

Enhancement of radiation effect on lung cancer A549 cells by gold nanoparticles.

Tao Li

e20505

Evaluation of different treatment strategies between right-sided and left-sided pneumonectomy for stage I-IIIA non-small cell lung cancer patients.

Ziping Wang

8524

Final overall survival for CSLC 0501: Phase 3 study of adjuvant versus neoadjuvant chemotherapy with docetaxel combined carboplatin for resectable stageⅠB-ⅢA non-small cell lung cancer.

Xue-ning Yang

8508

Neoadjuvant chemo/immunotherapy for the treatment of stages IIIA resectable non-small cell lung cancer (NSCLC): A phase II multicenter exploratory study—NADIM study-SLCG.

Mariano Provencio-Pulla

8521

Nivolumab plus cisplatin/pemetrexed or cisplatin/gemcitabine as induction in resectable NSCLC.

Nathaniel R. Evans

TPS8582

Phase II randomized clinical trial comparing immunotherapy plus stereotactic ablative radiotherapy (I-SABR) versus SABR alone for stage I, selected stage IIa or isolated lung parenchymal recurrent non-small cell lung cancer: I-SABR.

Joe Y. Chang

TPS8580

Population-based study predicting the probability of death resulting from non-small cell lung cancer (NSCLC) and other causes among NSCLC patients with surgery.

Bo Jia

8525

Post-operative radiation therapy (PORT) in resected non-small cell lung cancer (NSCLC): An updated population based analysis.

Stephen Shamp

8522

Prognostic factors in early stage lung cancer patients: Retrospective single center data.

Ozkan Alan

e20500

Sub-lobar lung resections in patients with non-small cell lung cancer associated with positive nodes: Incidence, risk factors, and prognostic variables.

Kerri McKie

e20507

The comparison of tumor mutational burden (TMB) in patients of early and late stage lung adenocarcinoma in China.

Kai Zhang

8520

The population-based impact of adjuvant chemotherapy (CTx) on outcomes in AJCC6 stage IB non-small cell lung cancer (NSCLC).

Rahul Krishan Arora

8523

Weekly nab-paclitaxel plus carboplatin as neoadjuvant therapy for IIIA-N2 lung squamous cell carcinoma: A prospective phase II study.

Jian- Quan Zhu

e20501